TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21739693

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group (warming needle moxibustion, once a day for 10 days)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Chinese medicine group (Simo Decoction oral solution, three times daily for 10 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 105
Study: 18785964

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subconjunctival saline (control)
Number of subjects: 16
Study: 16723428

Group type: EXPERIMENTAL
Intervention: Ornish Program for Reversing Heart Disease
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 12082498

Group type: EXPERIMENTAL
Intervention: Mercury and aneroid sphygmomanometers
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Sphygmomanometers
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Blood pressure recording audit
Number of subjects: 131
Study: 10434237

Group type: EXPERIMENTAL
Intervention: Azithromycin (1200 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7844679

Group type: EXPERIMENTAL
Intervention: Unwashed, older packed red blood cells
Number of subjects: 100

Group type: COMPARATOR
Intervention: Washed, younger packed red blood cells
Number of subjects: 100
Study: 2193272

Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resection of endometriosis (Control)
Number of subjects: 26
Study: 396930

Group type: EXPERIMENTAL
Intervention: mezlocillin (Baypen)
Number of subjects: 701
Study: 29746150

Group type: EXPERIMENTAL
Intervention: Triple-bundle (TB) anatomic reconstruction using semiconjoint tendon (SCT) and coracoacromial ligament (CAL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Modified Weaver-Dunn (WD) reconstruction
Number of subjects: 12
Study: 25709054

Group type: EXPERIMENTAL
Intervention: Linear Progression (LP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Daily Undulating Progression (DUP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 26
Study: 25601214

Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (n=134)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (18-months delayed GSD, n=66)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (women)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (women)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immediate GSD intervention (men)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 200
Study: 23588309

Group type: EXPERIMENTAL
Intervention: 600 mg rifampin once daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20367136

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT) after failing R-CHOP
Number of subjects: 185

Group type: COMPARATOR
Intervention: Autologous stem cell transplant (ASCT) after failing CHOP
Number of subjects: 185
Study: 18720267

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BMP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Methadone (MMP)
Number of subjects: 56
Study: 16841662

Group type: EXPERIMENTAL
Intervention: Pricking collateral blood therapy (PCBT) combined with massage therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Massage therapy alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (PCBT + massage and massage alone)
Number of subjects: 60
Study: 12434720

Group type: EXPERIMENTAL
Intervention: Intravenous argatroban infused at a rate of 1.25 micrograms/kg/min for 100 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single oral 7.5-mg dose of warfarin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Argatroban administered alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coadministration of argatroban and warfarin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Argatroban administered alone or with warfarin
Number of subjects: 12
Study: 9707362

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 3 days)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Quinine (10 mg/kg per 8 hourly for 5 days)
Number of subjects: 721
Study: 8523286

Group type: EXPERIMENTAL
Intervention: 3.5 mm self-sealing incision (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4.0 mm self-sealing incision (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.0 mm incision with one radial suture (Group C)
Number of subjects: 60
Study: 2234708

Group type: EXPERIMENTAL
Intervention: Cold knife conization with Sturmdorf sutures
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cold knife conization without sutures
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cone height of 20 mm or less
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cone height greater than 20 mm
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cytobrush sampling
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cotton swab sampling
Number of subjects: 183
Study: 368538

Group type: EXPERIMENTAL
Intervention: 3 mg of prazosin
Number of subjects: 16

Group type: COMPARATOR
Intervention: 75 mg of hydrallazine
Number of subjects: 16
Study: 29734840

Group type: EXPERIMENTAL
Intervention: EnhanceFitness (EF) program, 1-hour session held three times a week for at least 4 months, continued for up to 12 months.
Number of subjects: 1295
Study: 29023233

Group type: EXPERIMENTAL
Intervention: Intervention with compañeros
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control without compañeros
Number of subjects: 189
Study: 25336239

Group type: EXPERIMENTAL
Intervention: HbA1c < 6.9%
Number of subjects: 149

Group type: COMPARATOR
Intervention: HbA1c ≥ 6.9%
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 149
Study: 24947719

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 23010344

Group type: EXPERIMENTAL
Intervention: Tanezumab (20 mg, single intravenous dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19200356

Group type: EXPERIMENTAL
Intervention: Gastrointestinal nurse practitioner (GNP) follow-up
Number of subjects: 175

Group type: COMPARATOR
Intervention: GP follow-up
Number of subjects: 175
Study: 18210987

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15110545

Group type: EXPERIMENTAL
Intervention: Educational program (first questionnaire, first lesson for 2 hours, second lesson, second questionnaire)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Control (questionnaires only)
Number of subjects: 1676
Study: 11264625

Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 9830646

Group type: EXPERIMENTAL
Intervention: Gel containing silicon dioxide, aloe vera, and allantoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control gel with silicon dioxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel with all 3 active substances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified crossover design with all subjects from study II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study I and Study III results
Number of subjects: 0
Study: 7473467

Group type: EXPERIMENTAL
Intervention: Baseline values of disability and pain
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline pain
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Other baseline characteristics
Number of subjects: 95
Study: 29568100

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1754
Study: 27034119

Group type: EXPERIMENTAL
Intervention: VA bursts during optimal reperfusion (TIMI 3, stable ST-recovery, and MBG 3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No VA bursts during optimal reperfusion (TIMI 3, stable ST-recovery, and MBG 3)
Number of subjects: 126
Study: 24768221

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Locking intramedullary nail
Number of subjects: 40
Study: 24320801

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20597872

Group type: EXPERIMENTAL
Intervention: Low-dose transpupillary thermotherapy (TTT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98
Study: 19332985

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral iron protein succinylate (80 mg/day)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral iron protein succinylate
Number of subjects: 76
Study: 16785154

Group type: EXPERIMENTAL
Intervention: CC/hMG/cetrorelix protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: buserelin long protocol
Number of subjects: 120
Study: 15472846

Group type: EXPERIMENTAL
Intervention: Guideline implementation for the treatment of CAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospitals (external comparison group)
Number of subjects: 0
Study: 11041314

Group type: EXPERIMENTAL
Intervention: Acute hydrocortisone (100 mg, orally 11 h before)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic hydrocortisone (20 mg twice a day for 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9309369

Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg o.d.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg b.i.d.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (AMX/CA) 500 mg/125 mg t.i.d.
Number of subjects: 450
Study: 8323935

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction program
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Physician-delivered anticipatory guidance
Number of subjects: 89

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 89
Study: 2939862

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suxamethonium 1.6 mg kg‐1 plus infusion
Number of subjects: 30
Study: 31285357

Group type: EXPERIMENTAL
Intervention: Tight control (TC) strategy with adalimumab (40 mg sc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom-based clinical management (CM)
Number of subjects: 0
Study: 29884605

Group type: EXPERIMENTAL
Intervention: Year-long online lifestyle intervention for weight loss
Number of subjects: 67
Study: 27494932

Group type: EXPERIMENTAL
Intervention: Snack Track School app (gamified monitoring app)
Number of subjects: 1400
Study: 23875718

Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-based patient education programme (group and individual education)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 141
Study: 22633843

Group type: EXPERIMENTAL
Intervention: Couple-based prevention program
Number of subjects: 209

Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 209
Study: 20667854

Group type: EXPERIMENTAL
Intervention: Epidural cortical stimulation during intensive speech-language therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intensive speech-language therapy without epidural stimulation (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subjective caregiver ratings (Investigational participants)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Functional imaging (Investigational participants)
Number of subjects: 8
Study: 18317336

Group type: EXPERIMENTAL
Intervention: Aspheric design soft contact lenses (Biomedics 55 Evolution, CooperVision)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spherical design soft contact lenses (Biomedics 55, CooperVision)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both lens designs (aspheric and spherical)
Number of subjects: 20
Study: 16032618

Group type: EXPERIMENTAL
Intervention: Social services intervention
Number of subjects: 84
Study: 11853795

Group type: EXPERIMENTAL
Intervention: STI571
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 8
Study: 10027447

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 31) with targeted oxygen delivery index (DO2I) value of > 600 mL/min/m2
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n = 32) with conventional therapy and normal targeted oxygen delivery
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 7670005

Group type: EXPERIMENTAL
Intervention: DBM/Ara-C/Cy conditioning
Number of subjects: 11

Group type: COMPARATOR
Intervention: TBI/Cy conditioning
Number of subjects: 11
Study: 1675225

Group type: EXPERIMENTAL
Intervention: Growth hormone (bolus injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6185041

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg base per body weight every eight hours for 14 days (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quinine adjusted to body surface area based on an adult dose of 500 mg base eight hourly for 14 days (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups treated with quinine
Number of subjects: 50
Study: 30680448

Group type: EXPERIMENTAL
Intervention: Strength-type RT (3 sets of 6-8 RM with 3-min rest)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endurance-type RT (3 sets of 20-25 RM with 60-s rest)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 25
Study: 28449320

Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 25983022

Group type: EXPERIMENTAL
Intervention: TJ-14
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 24630956

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon-bone (QTB) graft
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 51
Study: 22943931

Group type: COMPARATOR
Intervention: AZD1656 (up to 180 mg)
Number of subjects: 0
Study: 19953987

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 17575340

Group type: EXPERIMENTAL
Intervention: Continuous responding with targets separated by less than 60 degrees of spatial angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrete responding with targets separated by greater than 60 degrees of spatial angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants allowed to correct movements after initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard task without corrections
Number of subjects: 0
Study: 15323576

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine 4mg
Number of subjects: 428

Group type: COMPARATOR
Intervention: Intermittent subcutaneous apomorphine injections
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine infusions
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Apomorphine challenge test
Number of subjects: 428

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 428
Study: 11731749

Group type: COMPARATOR
Intervention: Mannitol 0.5 g.kg‐1 as bolus at the start of skin incision, and postoperatively 0.5 g.kg‐1 daily three times a day for 3 days (72 hrs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mannitol 0.25 g.kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml.h‐1 intraoperatively and mannitol 0.25 g.kg‐1 daily three times a day for 3 days plus HTS in the concentration of 3% in the first day and 2% and 1% the second and the third day after surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3% HTS 3.5 ml kg‐1 as bolus at the start of skin incision plus 3% HTS, 20 ml hr‐1 intraoperatively and 3% HTS, 20 ml h‐1 on the first day and 2% and 1% the second and the third day after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mannitol 0.5 g.kg‐1 and Mannitol 0.25 g.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3% HTS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30

Group type: COMPARATOR
Intervention: Groups M and MH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group H
Number of subjects: 30
Study: 9165314

Group type: EXPERIMENTAL
Intervention: Objective group (passing the 12 mm barium pill test)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Subjective group (alleviation of dysphagia)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Objective group (Part 2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Objective group (long-term follow-up)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pill test (overall correlation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Passing the pill test 1 week after dilation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Failing the pill test
Number of subjects: 23
Study: 7965438

Group type: EXPERIMENTAL
Intervention: Cefaclor metabolites
Number of subjects: 39

Group type: COMPARATOR
Intervention: Immediate hypersensitivity reactions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonaffected control subjects
Number of subjects: 39
Study: 3593990

Group type: EXPERIMENTAL
Intervention: Regimen A (6 months of cyclophosphamide, adriamycin, and fluorouracil followed by 6 months of cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Regimen B (12 months of CMFVP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both regimens with tamoxifen 20 mg bid for patients with positive estrogen receptor status
Number of subjects: 41
Study: 28072667

Group type: EXPERIMENTAL
Intervention: Vein visualization device (S)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 129
Study: 28104469

Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention consisting of weekly health education and 3 moderate-to-vigorous physical activity sessions/week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control condition receiving health information and laboratory testing results
Number of subjects: 160
Study: 26206644

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo injection)
Number of subjects: 100
Study: 23797771

Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Chemotherapy (C)
Number of subjects: 427
Study: 21192148

Group type: EXPERIMENTAL
Intervention: Supportive family presence
Number of subjects: 50

Group type: COMPARATOR
Intervention: No supportive family presence
Number of subjects: 50
Study: 19436693

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg daily
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 6800
Study: 17097394

Group type: EXPERIMENTAL
Intervention: BoNTA1 (20 U)
Number of subjects: 62

Group type: COMPARATOR
Intervention: BoNTA2 (50 U)
Number of subjects: 62
Study: 14767589

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (6-week self-help manual)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 104
Study: 11589758

Group type: EXPERIMENTAL
Intervention: Continuous 50 Hz magnetic field exposure (100 microT rms)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermittent 50 Hz magnetic field exposure (100 microT rms)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham exposure (no magnetic field)
Number of subjects: 21
Study: 9508204

Group type: EXPERIMENTAL
Intervention: GM‐CSF 125 microg/m2 per day for 8 days
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 7905041

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 7
Study: 2537787

Group type: EXPERIMENTAL
Intervention: Kabi 2165, 2,500 anti‐Xa units twice a day (group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Kabi 2165, 2,500 anti‐Xa units twice a day during the first 48 h postoperatively and then 5,000 anti‐Xa units once a day (group B)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Adjusted-dose standard heparin, monitored by activated partial thromboplastin time (group C)
Number of subjects: 124
Study: 4934187

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 730

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 730
Study: 31850603

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy (NRT)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 712
Study: 29863535

Group type: EXPERIMENTAL
Intervention: Inverted ILM flap technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional ILM peeling (ILMP group)
Number of subjects: 24
Study: 29099972

Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of ketamine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26665676

Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine on demand
Number of subjects: 117

Group type: COMPARATOR
Intervention: 50 mg sertraline qd for one month
Number of subjects: 117